The "double grafted tumor system", proposed to find effector cells in the analyses of antitumor effect of BRMs.
The antitumor effects of three biological response modifiers (BRMs; PSK, IFN alpha A/D and OK432) and two chemotherapeutics (Mitomycin C and Neocarzinostatin) in a new experimental mouse model, the "double grafted tumor system," were evaluated. BALB/c mice received simultaneous inoculations of Meth A fibrosarcoma cells on right flank (1 x 10(6) cells) and left flank (2 x 10(5) cells) on day 0, and drugs were given intratumorally into the right-flank tumor on day 3. The growth of the left-flank tumor was the real target for the evaluation of a given drug after 21 days. All tested five agents successfully cured the drug-injected right tumor with a pre-determined optimum dose. In addition, PSK, OK432, IFN alpha A/D and MMC among the five, inhibited the left-flank tumor, whereas no inhibition was observed when treated with NCS. To understand the mechanism by which the antitumor effect of the above four agents is able to influence the growth of tumor on the other side, tumor cells (2 x 10(5) cells) inoculated only into the left flank were treated with drugs given subcutaneously to the right flank (single tumor system). Among the four, MMC exhibited an effect similar to that obtained in the double tumor system, and IFN alpha A/D showed a less pronounced but still definite antitumor effect. However, PSK and OK432 failed to express anti-tumor effect in the single tumor system. These results obtained with PSK, OK432 and IFN alpha A/D suggest that the effect of the drug on the left-tumor may be mediated by certain effector cells, which are specifically induced by injection of the drug, in the right-tumor tissues. When effector cell analysis was conducted with spleen cells obtained after PSK treatment by means of intratumoral adoptive transfer into 3-day Meth A bearing recipients, these cells were shown to be Lyt-1+2(-)-T and L3T4(+)-T cell.
Kohya
H
H
Department of Bacteriology, Tohoku University School of Medicine, Sendai, Japan.
Ebina
T
T
Yamaguchi
T
T
Ishida
N
N
D000818:Animals; D000906:Antibodies / Q000276:immunology; D000970:Antineoplastic Agents; D002478:Cells, Cultured; D003165:Complement System Proteins / Q000276:immunology; D005354:Fibrosarcoma / Q000139:chemically induced / Q000276:immunology / Q000628:therapy*; D007116:Immunization, Passive; D007155:Immunologic Factors / Q000494:pharmacology*; D007370:Interferon Type I / Q000494:pharmacology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D016685:Mitomycin; D008937:Mitomycins / Q000494:pharmacology; D009368:Neoplasm Transplantation; D010641:Phenotype; D010844:Picibanil / Q000494:pharmacology; D011134:Polysaccharides / Q000494:pharmacology; D013154:Spleen / Q000166:cytology; D009353:Zinostatin / Q000494:pharmacology
D000906:Antibodies; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D007370:Interferon Type I; D008937:Mitomycins; D011134:Polysaccharides; D010844:Picibanil; D016685:Mitomycin; D003165:Complement System Proteins; D009353:Zinostatin